Advertisement vbandhakavi, Author at Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

AstraZeneca targets $80bn revenue by 2030

The company said it aims to achieve this target by registering growth in its current portfolio in biopharmaceuticals, oncology, and rare diseases.  The effort also includes the launch